Background/Aims: Pancreatic cancer is an aggressive malignancy as a result of highly metastatic potential. The current study was carried out to alter the expression of LINC01121 in pancreatic cancer, with the aim of elucidating its effects on the biological processes of cell proliferation, migration, invasion, and apoptosis. We hypothesized that both the GLP1R gene and cAMP/PKA signaling pathway participate in the aforementioned process. Methods: Microarray data (GSE14245, GSE27890 and GSE16515) and annotating probe files linked to pancreatic cancer were downloaded through the GEO database. The Multi Experiment Matrix (MEM) site was used to predict the target gene of lncRNA. Both pancreatic cancer tissues (n = 56) and paracancerous tissues (n = 45) were collected from patients diagnosed with pancreatic cancer. Immunohistochemistry was applied to identify the positive expression rate of GLP1R protein. Isolated pancreatic cancer cells and PANC-1 cells were independently classified into the blank, negative control (NC), LINC01121 vector, siRNA-LINC01121, siRNA-GLP1R and siRNA-LINC01121 + siRNA-GLP1R groups. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blot analysis were applied to detect the expressions of LINC01121, GLP1R, cAMP, PKA, CREB, Bcl-2, Bad and PCNA. Cell proliferation, migration, invasion, cycle progression, and apoptosis were examined by MTT assay, scratch test, Transwell assay and flow cytometry analyses of Annexin V-FITC/PI staining. Results: Observations were
made indicating that LINC01121 was highly expressed, while low expressions of GLP1R in pancreatic cancer were detected based on microarray data, which was largely in consistent with the data collected of LINC01121 and GLP1R within the tissues. The target prediction program and luciferase activity analysis was testament to the notion suggesting that GLP1R was indeed a target of LINC01121. In contrast to the blank and NC groups, the LINC01121 vector group exhibited increased expressions of LINC01121; decreased mRNA and protein levels of GLP1R, Bad, cAMP, and PKA; increased protein levels of CREB, Bcl-2, PCNA, p-PKA and p-CREB; increased cell proliferation, migration and invasion; and decreased cell apoptosis. There was no significant difference detected among the blank, NC, and siRNA-LINC01121 + siRNA-GLP1R groups, except that decreased LINC01121 expression was determined in the siRNA-LINC01121 + siRNA-GLP1R group. Parallel data were observed in the pancreatic cancer cells and PANC-1 cells. Conclusion: The current study presents evidence indicating that LINC01121 might inhibit apoptosis while acting to promote proliferation, migration, and invasion of pancreatic cancer cells, supplementing the stance held that LINC01121 functions as a tumor promoter by means of its involvement in the process of translational repression of the GLP1R and inhibition of the cAMP/PKA signaling pathway.
.Introduction
Pancreatic cancer is an aggressive form of cancers accompanied by a high incidence of death. At present, there is a limited amount of effective treatments for the condition [1] . Metastasis represents the most common factor associated with cancer-related death, particularly in cases of pancreatic cancer, where metastatic disease is detected among the majority of patients, with a scarce number of patients exhibiting a durable response to radiation therapy or chemotherapy [2] . Since 1997, gemcitabine has been widely regarded as the standard first-line therapy for metastatic pancreatic cancer, while most subsequent phase 3 studies involving patients with advanced pancreatic cancer are yet to achieve any significant improvements regarding pancreatic survival rates [3] . Although gemcitabine therapy is the standard first-line treatment approach, many patients have displayed a limited response to gemcitabine therapy and combination treatment, with targeted treatments generally disappointing [4] . In addition, clinical statistics have indicated that patients who receive curative resection are still confronted with a poor prognosis represented by a very low 5-year survival rate of less than 20% [5] . Therefore, an urgent requirement exists in the form of identifying an effective treatment for pancreatic cancer.
Long non-coding RNAs (lncRNAs) are a group of non-protein-coding transcripts of more than 200 nucleotides in length, which play primary roles in the processes of tumor development and progression [6] . Various studies have indicated the significant role played by lncRNAs in the modulation of genes at the transcriptional, post-transcriptional and chromosomal levels in addition to possessing an array of distinctive biological functions. Interestingly, microarray data (GSE14245 and GSE27890) obtained from the GEO database illustrated LINC01121 is highly expressed in pancreatic cancer, a finding that motivated us to elucidate its specific role in pancreatic cancer. In addition, in connection with the target prediction program (Multi Experiment Matrix), GLP1R was presumed to be a target of LINC01121. A microarray dataset, GSE16515, found that low levels of GLP1R are expressed in cases of pancreatic cancer. As previously reported, the activation of glucagonlike peptide-1 receptor (GLP1R) inhibits growth, while promoting the apoptosis of human pancreatic cancer cells in a cAMP-dependent manner [7] . A previous study also provided insight in the form demonstrating that cAMP could recover the tumor suppressive functions of PKA by acting as a molecular brake in cancer cell migration in cases of pancreatic ductal adenocarcinoma [8] . Therefore, the central objective of the present study was to investigate the role by which lncRNA LINC01121 influences the growth and apoptosis of pancreatic cancer cells by targeting GLP1R via the cAMP/PKA signaling pathway, in a bid to unearth an effective therapy for pancreatic cancer.
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Bioinformatics prediction
Microarray data (GSE14245, GSE27890, and GSE16515) and annotating probe files related to pancreatic cancer were downloaded from the GEO database and detected using the Affymetrix Human Genome U133 Plus 2.0 Array. The affy installation package of R software was used to process background correction and normalization of chip data [9] . Next, linear model-empirical Bayesian statistics in the limma installation package combined with the application of a traditional t-test was performed for the nonspecific filtration of gene expression data to screen the differentially expressed rates of lncRNA [10] . The Multi Experiment Matrix (MEM, http://biit.cs.ut.ee/mem/) site was employed to predict the differentially expressed lncRNA. MEM, as a web-based tool, was used to conduct co-expression queries on large collections of gene expression experiments. MEM possesses a wide variety of publicly available gene expression datasets of distinct tissues, diseases and conditions, arranged by species and microarray platform types [11] . The WebGestalt database was used for KEGG enrichment analysis of the target gene to identify the major biochemical metabolic pathways and signaling pathways involved [12] .
Study subjects
Pancreatic cancer specimens and paracancerous tissues were collected from patients diagnosed with pancreatic cancer at the First Affiliated Hospital, School of Medicine, Zhejiang University. There were 56 patients with pancreatic cancer (35 males and 21 females; age: 30-85 years; mean age: 58.68 ± 8.29 years) in the pancreatic cancer tissue group. Forty-five specimens were selected and placed into the paracancerous tissue group. Pathological examinations were subsequently conducted on the diseased tissues. Based on the international pancreatic cancer tumor-node-metastasis (TNM) staging (International Union Against Cancer, 1987), pancreatic cancer cells were classified into stage I (19 cases), stage II (17 cases) and stage III (20 cases). We subsequently classified the patients diagnosed with pancreatic cancer into four molecular subtypes (Bailey et al, 2016) [13] including (1) squamous (n = 18); (2) pancreatic progenitor (n = 11); (3) immunogenic (n = 11); and (4) aberrantly differentiated endocrine exocrine (ADEX, n = 16). All specimens of pancreatic cancer tissues and paracancerous tissues were cut into small blocks and promptly placed into a frozen tube, stored in liquid nitrogen, and placed into a freezer at -80°C. All patients participating in this section of the experiment did so after agreeing to sign informed written consent documentation, which was subsequently approved by the clinical laboratory ethics committee of the First Affiliated Hospital, School of Medicine, Zhejiang University.
Hematoxylin-Eosin (HE) staining
All specimens were fixed in 10% formaldehyde, embedded in conventional paraffin and sliced into 4 μm thick specimens. The specimens were dewaxed twice with xylene, 15 min/time, twice immersed in absolute ethanol for 5 min in addition to the use of 80% and 90%, ethanol for 5 min each followed by rinsing under running tap water for 5 min. The specimens were stained with hematoxylin (H8070, Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) for 5 min and then washed until a blue color developed. The slices were rapidly differentiated by 1% hydrochloric acid ethanol and washed until a blue color developed. The slices were stained with eosin (PT001, Bogoo Biotechnology Co., Ltd, Shanghai, China) for 2 min. The slices were dehydrated twice by 80% and 90% graded ethanol for 5 min, followed by the use of absolute ethanol for 5 min, clearing in xylene twice, and finally sealed with neutral balsam and observed under a light microscope (DMM-300D, Shanghai Caikon Optical Instrument Co., Ltd., Shanghai, China). pH 7.4), 5 min each. After the slices were dried, biotinylated sheep anti-mouse IgG secondary antibody was added (1:1000, ab6789, Abcam Inc., Cambridge, MA, USA) for 30 min and incubated at 37°C. The chromogenic agent diaminobenzidine (DAB) was prepared through the addition of 1 mL of distilled water to three reagents, namely A, B and C of DAB (each 1 drop) (DA1010, Solarbio Science & Technology Co., Ltd., Beijing, China), which were then mixed in an even manner and stored in a refrigerator at 4°C. The slices were then washed 3 times with PBS, 5 min each. DAB was used for the development of the specimens, and the slices were preserved in a darkroom for 8 min at room temperature, followed by washing under running water for 5 min, and additional hematoxylin staining for 3 min, differentiation with 1% hydrochloric acid alcohol for 5 s and water immersion for 10 min until a blue color developed. The slices were sealed with neutral balsam, and photographed and observed under a light microscope. The cells with varying degrees of yellow-brown color in the cytoplasm were regarded as positive. Three non-overlapping visual fields with an equal area (× 200) were selected from each slice in order to calculate the number of positive cells using Japanese Nikon imaging analysis software.
Dual-luciferase reporter assay
The online forecasting website lncRNA Targets (http://www.herbbol.org:8001/lrt/) was used to predict the target gene of LINC01121. PANC-1 (CRL-1469, ATCC, Manassas, VA, USA) and HEK-293T (AT-1592, ATCC, Manassas, VA, USA) cells were inoculated into a 24-well plate followed by 24 h of culturing. Artificially synthesized GLP1R 3'UTR gene fragments were introduced into the pMIR-reporter (Promega, Madison, WI, USA) using endonuclease loci SpeI and Hind III. The complementary sequence mutation sites of seed sequences were designed using the GLP1R wild type (Wt). After which the digestion of restriction endonuclease, the target fragment was inserted into the pMIR-reporter plasmid through the application of the T4 DNA ligase. The sequenced luciferase reporter plasmids, Wt-GLP1R or mutant (Mut-GLP1R) recombinant plasmids were transfected with LINC01121 into HEK-293T cells (Shanghai Beinuo Biotechnology Co., Ltd, Shanghai, China). After transfection for 48 h, the cells were harvested and lysed. A luciferase assay kit was applied to detect luciferase activity.
Isolation, culture and identification of pancreatic cancer cells
Pancreatic cancer tissues were cut into 1-mm 3 pieces with ophthalmic scissors. The tissues were added to 3 mL of digestive enzyme (including 0.1% type I collagenase and 0.01% trypsin) and digested in a 37°C water bath for 80 min. Next, 2 mL of digestive enzyme was added again, and the tissues were again digested in a 37°C water bath for 30 min. The tissues were then added to 3 mL of M199 culture medium (31100035, Gibco Company, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS) (16000-044, Gibco Company, Carlsbad, CA, USA). Next, the tissues were centrifuged for 10 min at 1000 r/min. The supernatant was discarded, and the cell sediment was mixed with 3 mL of M199 culture medium containing 10% FBS and incubated at 37°C in a 5% CO 2 (ZXKR-1150, Shanghai Zhicheng Analytical Instrument Manufacturing Co., Ltd., Shanghai, China). Cell growth was observed under a microscope, with the culture medium changed regularly every 2 days. When the cells had reached approximately 80% confluency, the primary cell medium was absorbed, and the cells were washed 3 times with PBS. The cells were then rinsed with 0.25% trypsin solution and observed under a microscope. After most of the cells were observed to be round in shape, M199 culture medium containing 10% FBS was added to terminate the digestion process. After gentle dissociation of the cells with pipette tips, the cell suspension was cultured in a 5% CO 2 incubator at 37°C, with the culture medium changed at regular 3 day intervals. Cell morphology was observed under an inverted microscope (IX53, Olympus Optical Co., Ltd, Tokyo, Japan). The cell suspension was inoculated onto small glass slides, fixed with 10% formalin for 30 min and washed with PBS. Sealing solution containing 0.1% Triton X-100 (B1276, Shanghai Xitang Biotechnology Co., Ltd. Shanghai, China) and 1% FBS was added to the cells, followed by incubation at room temperature for 1 h. After 3 washes with PBS, the cells were incubated with primary antibody (rabbit anti-cTnT antibody, 1:400) at 4°C overnight. Next, the cells were washed 3 times with PBS, followed by the addition of the primary antibody (1:400, rabbit anti-cTnT antibody), and incubation at 37°C for 30 min. The cells were washed again with PBS 3 times, 4',6-diamidino-2-phenylindole (DAPI) dye (1: 20) was added to stain nucleus, and the cells were then incubated at 37°C for 30 min. Finally, after washing with PBS, the cells were observed under a fluorescence microscope (BX53, Olympus Optical Co., Ltd, Tokyo, Japan). Cell grouping PANC-1 cells were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS at 37°C in an incubator with 5% CO 2 under saturated humidity. When cell adhesion had reached 80~90%, the cells were trypsinized with 0.25% trypsin and 0.02% ethylenediaminetetraacetate (EDTA) and passaged accordingly. The third generation of pancreatic cancer cells and PANC-1 cells were assigned into the blank group (not transfected with any plasmids), negative control group (NC, transfected with negative control plasmids), LINC01121 vector group (transfected with LINC01121 overexpression plasmids), siRNA-LINC01121 group (transfected with LINC01121 interference plasmids), siRNA-GLP1R group (transfected with GLP1R interference plasmids) and siRNA-LINC01121 + siRNA-GLP1R group (transfected with LINC01121 and GLP1R interference plasmids). After digestion with 0.25% trypsin, the cells were resuspended in 1 × 10 5 /mL by M199 culture medium containing 10% FBS and were inoculated into a 6-well culture plate. When the cells reached 70% confluence, the culture medium was replaced with serum-free M199 culture medium. The cells were cultured under controlled conditions with continuous nitrogen delivery and hypoxia. After 24 h of culture, the cell transfection process was subsequently performed. Serum-free Opti-MEM culture medium (200 µL; 31985070, Gibco Company, Grand Island, NY, USA) was used to dilute 6 µL of Lipofectamine 2000 (11668-019, Invitrogen Inc., Carlsbad, CA, USA) and 4 μg of target plasmids separately. The solutions were mixed separately and permitted to stand for 10 min at room temperature. The solutions were then mixed evenly and incubated for 20 min at room temperature. After discarding the primary culture medium in the 6-well plate, 60 μL of Opti-MEM culture medium was added to each well, and the transfection mixture was added to the corresponding cell culture wells. After culturing at 37°C in an incubator with 5% CO 2 for 6-8 h, the culture medium was replaced with a fresh complete medium. After 48 h of transfection, the cells were collected.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
The cancerous tissues from four molecular subtypes and paracancerous tissues were collected and cut into smaller pieces (1 mm 3 ) using ophthalmic scissors. The RNA extraction kit (10296010, Invitrogen Inc., Shanghai, China) was used to extract total RNA after cell transfection in pancreatic tissues in each group. After determination of RNA purity and integrity, the extracted RNA was then reverse-transcribed into cDNA using the PrimeScript RT Kit (RR014A, Takara Biotechnology Ltd., Beijing, China). The reverse-transcription reaction system was 10 μL. The reaction was performed at 37°C 3 times, each time for 15 min and at 85°C for 5 s. The primer sequences of LINC01121, GLP1R, 3',5' cyclic adenosine monophosphate (cAMP), protein kinase A (PKA), cAMP response element binding protein (CREB), B-cell lymphoma-2 (Bcl-2), Bcl-xL/Bcl-2-associated death promoter (Bad), proliferating cell nuclear antigen (PCNA) and betaactin (β-actin) were designed and synthesized by Takara Biotechnology Ltd., (Beijing, China) ( Table 1 ). According to the instructions of the PCR kit (KR011A1, Beijing Tiangen Biotech Co., Ltd., Beijing, China), the RT-qPCR reaction was performed. PCR was performed in a 25-μL volume containing 2.5 μL of 10 × PCR Buffer, 1.5 μL of 25 mmol/l MgCl 2, 0.5 μL of 10 mmol/l dNTP, 1 μL of 10 mmol/l Primer, 2.5 μ/l of 1 nmol/l P robe, 5 μ/l, 0.25 μL of Taq, 2.5 μL of cDNA and 15 μL of distilled water. The PCR amplification consisted of 40 cycles of pre-denaturation at 94°C for 5 min, denaturation at 94°C for 30 s, annealing at 58°C for 45 s, and extension at 72°C for 30 s, as well as a final extension step (72°C for 10 min). All reactions were performed in triplicate. Real-time quantitative fluorescence PCR (ABI 7500, ABI, Foster City, CA, USA) was used to detect gene expression. β-actin was regarded as an internal reference, and the 2 -ΔΔCt method was applied in order to calculate the relative expression of target genes. Each experiment was conducted 3 times. The formula applied was as follows: ΔΔCT = ΔCt experiment group -ΔCt control group and ΔCt = Ct target gene -Ct β-actin (P < 0.05).
Western blot analysis
The transfected cells were collected, added to the protein lysate (R0010, Beijing Solarbio Science & Technology Co., Ltd. Beijing, China) and cleaved at 3000 r/min. The cells were placed in a 4°C ice bath for 30 min and centrifuged for 15 min at 5000 r/min, followed by collection of the supernatant. The protein concentration was detected following the instructions of the bicinchoninic acid (BCA) Protein Quantification Kit (23225, Pierce, Rockford, IL, USA), and the concentration was adjusted to 1 μg/μL. The processed protein was added to each sample well, with 20 μg added into each sample per well. The protein samples were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (P1200, Beijing Solarbio Science & Technology Co., Ltd. Beijing, China), which was first performed at 80 V/cm and then adjusted to 120 V after entering the separation gel. In the event the samples were close to the bottom of the separation gel, the electrophoresis process was halted. The protein samples were then transferred to polyvinylidene fluoride (PVDF) membranes (HVLP04700, Millipore, Bedford, MA, USA) by means of semidry electrotransfer and then stained with Ponceau (P0012, Beijing Solarbio Science & Technology Co., Ltd. Beijing, China) to observe the protein transfer. The membranes were washed twice with Tris-buffered saline containing 0.1% Tween-20 (TBST), the proteins were sealed with 5% skimmed milk powder at room temperature for 2 h, followed by 3 TBST washes of the membrane. The diluted primary antibody mouse antihuman monoclonal antibody was added and incubated at 4°C overnight. GLP1R (1:500, ab186051), cAMP (1:50000, ab76238), PKA (1:25000, ab75993), CREB (1:1000, ab32515), Bcl-2 (1:1000, ab32124), Bad (1:2000, ab32445), PCNA (1:1000, ab18197), β-actin (1:1000, ab8227, Abcam), p-PKA (1:3000, ab75991) and p-CREB (1:5000, ab32096) were all obtained from Abcam Inc., Cambridge, MA, USA. The membrane was then washed 5 times with PBS, 5 min each time. The protein was then incubated with horse-radish peroxidase (HRP)-labeled goat anti-mouse IgG (Beijing Zhongshan Biotechnology Co., Ltd., Beijing, China, 1:5000). The membrane was immersed in electrochemiluminescence (ECL) luminous liquid (WBKLS0500, Pierce, Rockford, IL, USA), and the results were observed after developing in a dark room.
MTT assay
The isolated pancreatic cancer cells and PANC-1 cells at the logarithmic growth phase were inoculated into a 96-well plate with a density of 1 × 10 4 /well, with each group preset with 8 parallel holes. The control well was comprised exclusively of culture medium without cells. When the cells had reached approximately 70% confluency, 20 μL of 5 mg/mL MTT (ST316, Beyotime Biotechnology Co., Shanghai, China) was added to each well, and placed in an incubator at 37°C for 4 h. After the supernatant was discarded, the cells were washed with PBS, and 100 μL of dimethylsulfoxide (DMSO) (D5879, Sigma-Aldrich Chemical Company, St Louis MO, USA) was added to each well. After 10 min of shaking on a shaking table, the optical density (OD) value was measured at a wavelength of 492 nm in a microplate reader (MK3, Thermo, Pittsburgh, PA, USA). Cell viability = (OD experimental wells -OD control wells )/OD control wells. All experiments were performed 3 times, with the average values calculated.
Scratch test
Cells from the two cell lines after 48 h of transfection, deemed to be in good condition were collected and inoculated into a 6-well plate with at a density of 1 × 10 6 cells/well. When the cells had reached approximately 95% confluence, a 20-μL micropipette was used to create a vertical linear scratch in the 6-well plate. D-Hanks liquid was used to rinse and remove the falling cells. The cells were then added to a serum-free culture medium in order to continue the culturing process. After transfection for 48 h, images of the cells were acquired. Image-Pro Plus Analysis software (Media Cybernetics Company, USA) was applied to measure the distance of cell migration. All experiments were performed 3 times, with the average values calculated. 
Transwell assay
After 48 h of transfection, two cells were starved in serum-free culture medium for 12 h and digested in order to eliminate the effects of the serum. The cells were then washed twice with PBS. The serum-free Opti-MEMI culture medium (31985-070, Invitrogen Inc., Carlsbad, CA, USA) containing 10 g/L of bovine serum albumin (BSA) was used to suspend the cells, followed by the adjustment of the cell concentration to 2 × 10 6 cells/mL. The experiment was performed using a 24-well plate Transwell chambers with 8-μm pores (3413, American Corning Company, New York, USA), with 3 chambers set in each group. Prior to the experiment, 50 μL of Matrigel (40111ES08, Sigma-Aldrich Chemical Company, St Louis MO, USA) was placed in the chamber. After 48 h, 200 μL (4 × 10 4 cells) of a single-cell suspension of each group was added into the apical chamber of the Transwell chamber, while 650 μL of Opti-MEMI containing 10% FBS (31985-070, Invitrogen Inc., Carlsbad, CA, USA) was added to the basolateral chamber. The basolateral chamber was then cultured at 37°C in an incubator with 5% CO 2 for 12 h. Next, the basolateral chamber was then removed, washed with PBS, placed in methanol solution, fixed at room temperature for half an hour and stained with 0.1% crystal violet for 20 min. The upper cells of the microporous membrane were carefully removed using a cotton swab, and an inverted optical microscope was then employed in order to observe and collect images. Four visual fields were randomly selected to calculate the number of cells passing through the microporous membrane. All experiments were performed 3 times, and the results were presented using average values.
Flow cytometry
After 48 h of transfection, pancreatic cancer and PANC-1 cells were digested with 0.25% trypsin and were adjusted to 1 × 10 6 cells/mL. Cells (1 mL) were centrifuged at 1500 r·min -1 for 10 min, and the supernatant was abandoned. A ratio of 1 mL of cells to the addition of 2 mL of PBS was employed, followed by centrifugation. After the supernatant had been discarded, the cells were fixed in pre-cooled 70% ethanol and were placed at 4°C overnight. The cells were then washed twice with PBS on the following day, while cell suspension (100 μL) was added to 50 μg of propidium iodide (PI) dye containing RNAase and was filtered using a nylon mesh under dark conditions for 30 min. Flow cytometry (Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA) was used to record the red fluorescence of PI-stained cells at an excitation wavelength of 488 nm for cell cycle detection purposes.
Annexin V-fluorescein isothiocyanate (FITC)/PI double staining methods were applied in order to detect apoptosis among the two cell lines. The processed cells then underwent incubation in a 37°C incubator with 5% CO 2 for 48 h. The cells were then washed twice with PBS, centrifuged and re-suspended with 200 μL of binding buffer. Next, 10 μL of Annexin V-FITC (ab14085, Abcam Inc., Cambridge, MA, USA) was added to the cell suspension and 5 μL of PI, followed by gentle mixing and reaction for 15 min at room in conditions avoid of light. After the addition of 300 μL of binding buffer, flow cytometry (Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA) was performed to detect cell apoptosis using red fluorescence at a wavelength of 488 nm.
Statistical analysis
All the data were analyzed using SPSS 21.0 statistical software (SPSS Inc., Chicago, IL, USA). The measurement data were expressed in terms of mean ± standard deviation (SD). Comparisons between two groups were performed using t-test, while one-way analysis of variance (ANOVA) was applied for comparisons among multi-groups. The correlation between LINC01121 and GLP1R was analyzed using the Pearson's chi-squared statistics. P < 0.05 was an indicative of statistically significant difference.
Results
Selection of lncRNA LINC01121
Based on the analysis of the chips related to pancreatic cancer (GSE14245, GSE27890 and GSE16515), LINC01121 was determined to be highly expressed among the pancreatic cancer tissues, while low expressions of GLP1R were detected in the pancreatic cancer tissues (Fig. 1A-C) . As a result, lncRNA LINC01121 was selected for this study. In addition, we found a reciprocal correlation of LIN01121 and GLP1R based on GSE16515 (Fig. 1D) , which was further confirmed by Pearson correlation analysis using TCGA data (Fig. 1E) .
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Prediction of the target gene of lncRNA LINC01121
MEM was adopted to predict the target gene of lncRNA. GLP1R was revealed to be a target gene of lncRNA LINC01121 (Table 2 ) and was involved in the cAMP/PKA signaling pathway (Table 3) .
Histopathological observation of pancreatic cancer tissues and paracancerous tissues
The adenoid structure and pyknosis of the acinar cells were discovered in the pancreatic cancer tissues. An abundant amount of fibrous connective tissue was detected intercellularly, with the intercellular space observed to have broadened and was infiltrated by inflammatory cells. The nuclei in the paracancerous cells were observed to be elliptical in shape, with no signs of inflammatory cells (Fig. 2) .
Positive rate of GLP1R protein in pancreatic cancer tissues and paracancerous tissues
As illustrated in Fig. 3 , the GLP1R protein was brownish in appearance particularly in the cytoplasm and nucleus. Compared with the paracancerous tissues, the number of GLP1R-positive cells in the pancreatic cancer tissues was significantly decreased (P < 0.05)
Targeting relationship between LINC01121 and GLP1R
According to the online website (https://cm.jefferson.edu/rna22/), the following column showed the position where LINC01121 binds to the GLP1R 3'UTR. The free energy between them was ΔG = -106.24, with ΔG/n = -0.067. Therefore, GLP1R was considered to be a target gene of LINC01121 (Fig. 4A) . As depicted in Fig. 4B , when compared with the NC group, significant reductions in luciferase activity in the LINC01121 vector group were recorded, while marked increases in the siRNA-LINC01121 group were observed (both P < 0.05). RT-qPCR results revealed that GLP1R was decreased, while LINC01121 was elevated among the pancreatic cancer tissues compared with that of the paracancerous tissues (P < 0.05) (Fig. 4C) . The aforementioned data suggested that LINC01121 could inhibit GLP1R activity, while demonstrating that LINC01121 was negatively correlated with GLP1R among the pancreatic cancer tissues (Fig. 4D) .
The mRNA and protein expression levels of LINC01121, GLP1R, cAMP, PKA, CREB, Bcl-2, Bad, PCNA, p-PKA and p-CREB in pancreatic cancer cells and PANC-1 cells
As exhibited in Fig. 5 , compared with the blank group, no distinct differences in the NC group were detected (all P > 0.05). The LINC01121 vectors displayed increased LINC01121 expression, while the siRNA-GLP1R no alterations in the expression of LINC01121 were observed. Increases to both the expressions of Bcl-2 and PCNA; decreased expressions of GLP1R, cAMP, PKA, CREB and Bad; as well as reduced PKA and CREB phosphorylation were detected (all P < 0.05). However, siRNA-LINC01121 exposure was demonstrated to result in contrasting results due to the decreased expression levels of LINC01121. siRNA-LINC01121 + siRNA-GLP1R exposure led to a reduction in the expression of LINC01121 (P < 0.05). The two cell lines were noted to exhibit the same trends.
LINC01121 promotes pancreatic cancer cell and PANC-1 cell proliferation
MTT assay results indicated that compared with the blank and NC groups, no evident differences were shown regarding the growth conditions of the cells at 24 h, 48 h and 72 h among all groups (P > 0.05), while increased OD values were recorded at 48 h and 72 h in the LINC01121 vector and siRNA-GLP1R groups (all P < 0.05), with the OD values at 48 h and 72 
Fig. 4.
Targeting relationship between LINC01121 and GLP1R. Note: A, three binding sites of LINC01121 in GLP1R 3'UTR; B, dual-luciferase reporter assay was performed to detect luciferase activity; C, expression levels of LINC01121 and GLP1R in pancreatic cancer tissues and paracancerous tissues; D, analysis of the expression levels of LINC01121 and GLP1R in pancreatic cancer tissues; * , P<0.05, compared with the NC group; # P<0.05, compared with paracancerous tissues; GLP1R, glucagon-like peptide-1 receptor; NC, negative control; LINC01121, long intergenic non-protein coding RNA 1121. 
h exhibiting significant decreases in the siRNA-LINC01121 group (both P < 0.05) (Fig. 6 ). The two cell lines were noted to have illustrated the same trends.
LINC01121 promotes pancreatic cancer cell and PANC-1 cell migration
No notable difference in the siRNA-LINC01121 + siRNA-GLP1R group regarding the ability of cell migration compared with that of the blank and NC groups were observed (both P > 0.05), and the cell migration ability of the LINC01121 vector and siRNA-GLP1R groups were significantly increased (both P < 0.05), while the siRNA-LINC01121 group displayed distinct reduction of cell migration (P < 0.05) (Fig. 7) . Similar trends were recorded among the two cell lines.
LINC01121 promotes pancreatic cancer cell and PANC-1 cell invasion
As depicted in Fig. 8 , no significant difference in terms of cell invasion was detected between the blank and NC groups (P > 0.05). Compared with the blank and NC groups, cell invasion abilities were evidently increased in the LINC01121 vector and siRNA-GLP1R groups, while significant reductions in the siRNA-LINC01121 group were noted (all P < 0.05), with no notable differences in the siRNA-LINC01121 + siRNA-GLP1R group observed (P > 0.05). The same trends were observed in the two cell lines.
LINC01121 induces cell cycle arrest and inhibits apoptosis in pancreatic cancer cells and PANC-1 cells
No significant differences were found in the pancreatic cancer in terms of the parameters of cell cycle distribution and apoptosis in the blank, NC and siRNA-LINC01121 + siRNA- GLP1R groups (all P > 0.05). Compared with the blank and NC groups, the number of cells at the G0/G1 phase in the siRNA-LINC01121 group was notably increased, while reduced numbers at the S phase and increased in the G2 phase were recorded, as well as observations of evidently increased rates of apoptosis (all P < 0.05). The LINC01121 vector group was found to have exhibited contrasting results regarding the aforementioned findings (all P < 0.05) (Fig. 9, Fig. 10 ). The results indicated that LINC01121 overexpression as well as silencing of GLP1R expression could promote proliferation and suppress the apoptosis of pancreatic cancer cells. The two cell lines were again observed to have exhibited the same trends.
Discussion
Pancreatic cancer remains one of most the severe malignancies, representing a significant public health stumbling block [14] . Reports have highlighted an accumulating number of lncRNAs have been found to exert significant effects on the processes of development and metastasis in various types of cancers [15] . In the current study, we demonstrated that LINC01121 could act to enhance proliferation, migration and invasion of pancreatic cancer cells, while repressing cell apoptosis by targeting GLP1R via the inhibition of the cAMP/PKA signaling pathway. Without doubt, LINC01121 may function as a promising strategy for the treatment of pancreatic cancer in the near future.
Observations were made, indicating that LINC01121 was up-regulated in pancreatic cancer tissues, while the mRNA and protein levels of GLP1R were decreased when compared with that in paracancerous tissues. More recently, lncRNAs have been detected in various human cancers, including that of pancreatic cancer [16] . A previous study revealed that lncRNAs could function to modulate transcription through various mechanisms, including interactions with RNA binding proteins, inhibiting a major promoter of their target gene, or even acting as a co-activator of transcription factors [17] . During the present study, we demonstrated that GLP1R was a target gene of LINC01121. Moreover, based on the Genome Data Viewer, LINC01121 was determined to be located on chromosome 2p21, with indications that solute carrier family 3, member 1 (SLC3A1) share the same genetic locus with LINC01121. Reports have asserted an association between SLC3A1 expression in breast cancer cells and enhanced tumorigenesis in breast cancer [18] . Meanwhile, the expression of another lncRNA, MALAT1, was significantly higher in pancreatic the duct of adenocarcinoma than in paracancerous tissues [16] . In addition, GLP1, as an incretin hormone, stimulates the release of insulin and represses glucagon secretion from the pancreas in a glucose-dependent manner [19] . The activation of GLP1 and GIP1R has been found to result in non-glycemic effects on various tissues by expressing incretin receptors [20] . In general, GLP1 analogs activate GLP1R, which have been observed among pancreatic cancer tissues, while GLP1R expression in pancreatic cancer tissues has presented lower levels than in paracancerous tissues, indicating that lower GLP1R expression could well be associated with malignancy [7] . Consistently, the results of our study also revealed that greater expressions of LINC01121, but lower expression of GLP1, was more apparent in pancreatic cancer tissues than in paracancerous tissues. The current study indicated that LINC01121 could inhibit GLP1R expression, while GLP1R could inhibit the activation of the cAMP/PKA signaling pathway. The results of the present study identified GLP1R to be likely a target gene of LINC01121, capable of regulating the expression of GLP1R. According to a previous study, cAMP and cAMP-dependent PKA modulate multiple functions of cells in almost all eukaryotic cells [21] . The cAMP pathway is regarded as a crucial signaling pathway involved in different aspects of cell regulation, as well as possessing therapeutic potential in various kinds of human disease, including cancer [22] . Furthermore, many lines of evidence proved that the PKA pathway might be involved in the up-regulation of lncRNA HULC in liver cancer [23] . Similarly, it has been demonstrated that lncRNA LINC473 expression is highly activated in human decidualization by the cAMP signaling pathway [24] , which was also indicated in the present study, in the form of demonstrating the effect of lncRNA LINC01121 on the activation of the cAMP/PKA pathway.
A significant finding of the present study was in the form of the demonstration that LINC01121 could promote pancreatic cancer cell proliferation, migration and invasion, and suppress apoptosis. A recent report revealed that the down-regulation of lncRNA MALAT-1 could inhibit tumor cell proliferation, migration and invasion [25] . At present, consensus suggests that lncRNAs exert a crucial influence on the development and progression of pancreatic cancer [26] . Moreover, our data inferred that LINC01121 suppressed GLP1R expression but activated the cAMP/PKA pathway. Another study indicated that the activation of GLP1R inhibits growth and promotes the apoptosis of human pancreatic cancer cells [7] . In addition, the protective effects of GLP1 have been reported to be partly regulated via GLPIR through the activation of protein kinase C (PKC) β [27] . Based on the results of our study, we are of the opinion that LINC01121 could accelerate pancreatic cancer cell proliferation, migration and invasion and inhibit apoptosis by inhibiting the GLPIR and cAMP/PKA pathway. Although the cellular function of lncRNAs remains a mystery, our study contributes to a growing body of literature that supports the significance of lncRNAs in cellular biology.
Conclusion
lncRNA LINC01121 is highly activated in pancreatic cancer, while GLP1R is reduced in pancreatic cancer, while LINC01121 promotes the development and progression of pancreatic cancer through negative modulation of the cAMP/PKA signaling pathway. Therefore, the identification of LINC01121 in pancreatic cancer may provide assistance aiding in the facilitation of our understanding of the potential gene mechanisms associated with pancreatic cancer, which may well serve as a new target for the treatment of pancreatic cancer in the future. However, further study is required based on the specific date for patients diagnosed with pancreatic cancer.
